Latest Results From an Ongoing First-in-Human Phase 1a/B Study of NX-5948, a Selective Bruton's Tyrosine Kinase (BTK) Degrader, in Patients With Relapsed/Refractory CLL and Other B-Cell Malignancies
Year: 2024
Type: article
Authors: Kim Linton, Graham P. Collins, Francesco Forconi, Nirav N. Shah, Karan Dixit, Talha Munir, Zulfa Omer, Dima El-Sharkawi, Jeanette Doorduijn, Alvaro Alencar, Pam McKay, John Riches, Mary Gleeson, David Lewis, Allison Winter, Sarah Injac, Ted Shih, Srinand Nandakumar, May Tan, Ganesh Cherala, Erin Meredith, Alexey Danilov
Institutions: The Christie Hospital, Cancer Research UK Manchester Centre, Oxford University Hospitals NHS Trust, University Hospital Southampton NHS Foundation Trust, Medical College of Wisconsin, Northwestern University, St James's University Hospital, University of Cincinnati, Royal Marsden NHS Foundation Trust, Erasmus MC, Erasmus MC Cancer Institute, University of Miami, Sylvester Comprehensive Cancer Center, Beatson West of Scotland Cancer Centre, Queen Mary University of London, Barts Cancer Institute, Sarah Cannon Research Institute, Derriford Hospital, Cleveland Clinic, Nurix (United States), City Of Hope National Medical Center
Language: English
Subfield: Genetics
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4401878588